Dr. Paolo Fagone
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
19Years (2008-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications10 March 2011 in Aging
Journal Article
LSLinda S. Steelman
Linda S. Steelman
WCWilliam H. Chappell
William H. Chappell
SAStephen L. Abrams
Stephen L. Abrams
CKC. Ruth Kempf
C. Ruth Kempf
JLJacquelyn Long
Jacquelyn Long
JMJames A. McCubrey
James A. McCubrey +19
Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is often the result of genetic alterations in critical components in these pathways or upstream activators. Unrestricted cellular proliferation and decreased sensitivity to apoptotic-inducing agents are typically associated with activation of these pro-survival pathways. This review discusses the functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli. Crosstalk and commonly identified mutations that occur within these pathways that contribute to abnormal activation and cancer growth will also be addressed. Finally the recently described roles of these pathways in cancer stem cells, cellular senescence and aging will be evaluated. Controlling the expression of these pathways could ameliorate human health.
11 March 2011 in Oncotarget
Journal Article
WCWilliam H. Chappell
William H. Chappell
LSLinda S. Steelman
Linda S. Steelman
JLJacquelyn M. Long
Jacquelyn M. Long
RKRuth C. Kempf
Ruth C. Kempf
SAStephen L. Abrams
Stephen L. Abrams
JMJames A. McCubrey
James A. McCubrey +20
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
20 October 2012 in Oncotarget
Journal Article
JMJames A. McCubrey
James A. McCubreyLSLinda S. Steelman
Linda S. Steelman
WCWilliam H. Chappell
William H. Chappell
SAStephen L. Abrams
Stephen L. Abrams
RFRichard A. Franklin
Richard A. FranklinAMAlberto M. Martelli
Alberto M. Martelli
+16
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can result in pathway activation depending on the presence of upstream mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type (WT) RAF in the presence of mutant, activated RAS) and rapamycin can induce Akt activation. Targeting with inhibitors directed at two constituents of the same pathway or two different signaling pathways may be a more effective approach. This review will first evaluate potential uses of Raf, MEK, PI3K, Akt and mTOR inhibitors that have been investigated in pre-clinical and clinical investigations and then discuss how cancers can become insensitive to various inhibitors and potential strategies to overcome this resistance.
20 September 2012 in Oncotarget
Journal Article
JMJames A. McCubrey
James A. McCubreyLSLinda S. Steelman
Linda S. Steelman
WCWilliam H. Chappell
William H. Chappell
SAStephen L. Abrams
Stephen L. Abrams
GMGiuseppe Montalto
Giuseppe MontaltoAMAlberto M. Martelli
Alberto M. Martelli
+15
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTEN, TSC1, and TSC2 may also be activated/inactivated by mutations or epigenetic silencing. Upstream mutations in one signaling pathway or even in downstream components of the same pathway can alter the sensitivity of the cells to certain small molecule inhibitors. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of components of these cascades can contribute to: resistance to other pathway inhibitors, chemotherapeutic drug resistance, premature aging as well as other diseases. This review will first describe these pathways and discuss how genetic mutations and epigenetic alterations can result in resistance to various inhibitors.
15 April 2011 in Leukemia
Journal Article
LSL S Steelman
L S Steelman
RFR A Franklin
R A FranklinSAS L Abrams
S L Abrams
WCW Chappell
W Chappell
CKC R Kempf
C R Kempf
JMJames A. McCubrey
James A. McCubrey +10
25 March 2011 in Leukemia
Journal Article
AMA M Martelli
A M Martelli
CECamilla Evangelisti
Camilla EvangelistiWCW Chappell
W Chappell
SAS L Abrams
S L Abrams
JBJ Bäsecke
J Bäsecke
JMJames A. McCubrey
James A. McCubrey +9
About Me
Paolo Fagone obtained his BS degree in Biological Sciences at the University of Catania in 2003 and then graduated with an MS degree in Health Biology. He has been a Research Fellow at the Stellar-Chance Laboratories at the University of Pennsylvania, Philadelphia, for two years, after which he attended the School of Medicine of the University of Catania and graduated in Medicine and Surgery. He has been a Senior Scientist in the Immunopathology and Translational Immunopharmacology Laboratory, in the Department of Biomedical and Biotechnological Sciences at the University of Catania, where he worked since 2005. The research field of Paolo Fabrizio Fagone is mainly focused on the immunopathological mechanisms involved in immuno-inflammatory, autoimmune and cancer diseases. Main scientific skills: in vitro and in vivo preclinical models; expertise in biostatistics and silico analysis of "whole-genome profiling" data. Paolo Fabrizio Fagone was the Principal Investigator of a 12-month study, funded by the Lega Italiana per la Lotta contro i Tumori (LILT). Paolo Fabrizio Fagone actively participates in national and international scientific congresses, as a speaker and chairman. He is a reviewer of 10+ international peer-reviewed scientific journals. Paolo Fabrizio Fagone is a co-author of 100+ publications. He was Assistant Professor from 2020 to 2023, and he is now Associate Professor at the University of Catania, Italy.